The Readout Loud

Nov 14 2024 335 ep. 29 mins 2.7k
The Readout Loud Podcast artwork

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

  Business
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


331: AbbVie’s stumble, Amgen’s tumble and more election fallout

Nov 14 2024 30 mins  
Why are AbbVie executives feeling the M&A blues? What does it take to slice $12 billion from Amgen’s market value? And why are STAT’s D.C. correspondents working so hard? We talk about all that and more on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. It’s a “Chatty Cathy” episode! Elaine, Allison and Adam lead off with a discussion about

330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

Nov 07 2024 39 mins  
To dig into how the election results could affect all things biopharma, we brought on three guests for this episode: Lizzy Lawrence, STAT’s FDA reporter, Baird analyst Brian Skorney, and longtime biotech executive Daphne Zohar.

329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

Oct 31 2024 28 mins  
Adam, Allison, and Elaine get into the Halloween spirit this week, discussing their favorite candies — and Eli Lilly and Pfizer's surprise earnings reports. Then, they discuss what a Trump or Harris presidency could mean for health care and the biopharma industry, and what investors and biopharma executives think about either outcome.

328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

Oct 24 2024 33 mins  
Will an activist investor campaign against Pfizer lead to big changes at the struggling Pharma giant? Why are some experts questioning the regulatory standards used to approve gene therapies for Duchenne muscular dystrophy? What’s the difference between Novo Holdings and Novo Nordisk, and will it impact a $16 billion acquisition of Catalent? And what lies ahead for Robert F. Kenn

327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

Oct 17 2024 34 mins  
Elaine, Allison, and Adam chat about investors' interest in using CAR-T to treat autoimmune conditions, the latest developments with the supply of Eli Lilly’s blockbuster weight loss drug, and the invisible medical groups behind the dozens of telehealth platforms providing GLP-1 drugs. They also look back at STAT's two-day summit that brought together biopharma executives, scient

326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI

Oct 10 2024 40 mins  
First, biotech veteran John Maraganore calls in to discuss his new startup, City Therapeutics, this week's Nobel Prize awards, and the nerdy accolade he just received. Then STAT's Megan Molteni tells us about "CRISPR baby" scientist He Jiankui and his new cryptocurrency financier.

325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO

Oct 03 2024 32 mins  
Our colleague Mohana Ravindranath joins us to talk about Micky Tripathi, charged with coordinating how AI is used across different government agencies and more broadly across the health care industry. We also chat about some important biotech study readouts due before the end of the year, a new, well-funded obesity company, and the successful serial CEO running it. Finally, Adam an

From Tradeoffs: Race to the Bottom

Sep 28 2024 28 mins  
We’re excited to share the first episode in a new podcast series on generic drugs from Tradeoffs. It’s called ‘Race to the Bottom,’ and each week the show examines the problems undermining the generic drugs we all rely on — and how we could fix them. Take a listen, and we’ll see you next week.

324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug

Sep 26 2024 32 mins  
Our colleague Jonathan Wosen joins us to discuss the recent setbacks and wins in oncology R&D, including Genentech's decision to shut down its cancer immunology group, and the global ambitions of Akeso, the Chinese biotech behind Summit Therapeutics’ recent positive results. We also chat about the latest news in the life sciences, including Pfizer’s sudden announcement to pull

323: Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates

Sep 19 2024 35 mins  
Mizuho analyst Jared Holz joins us to discuss what the Federal Reserve's long-awaited decision to lower interest rates means for biotech stocks and startups. Elaine, Adam, and Allison also discuss the latest news in life sciences, including the use of cannabinoid receptor drugs in weight loss and the Lasker Awards, a.k.a. "America's Nobel."